Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

BMO maintains Novo Nordisk stock Outperform rating, $105 target ...

The company agreed to pay up to $2 billion for the rights to UBT251, a developmental weight-loss and obesity drug from Chinese pharmaceutical company United Bio-Technology (Hengqin), as it looks ...